相似文献
1
Targeted sequencing using a 47 gene multiple myeloma mutation panel (M(3) P) in -17p high risk disease.
Br J Haematol. 2015 Feb;168(4):507-10. doi: 10.1111/bjh.13171. Epub 2014 Oct 10.
2
Longitudinal analysis of 25 sequential sample-pairs using a custom multiple myeloma mutation sequencing panel (M(3)P).
Ann Hematol. 2015 Jul;94(7):1205-11. doi: 10.1007/s00277-015-2344-9. Epub 2015 Mar 7.
3
The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy.
Genes Chromosomes Cancer. 2011 Oct;50(10):765-74. doi: 10.1002/gcc.20899.
4
The spectrum of TP53 mutations in bladder carcinoma.
Genes Chromosomes Cancer. 1994 Feb;9(2):108-18. doi: 10.1002/gcc.2870090206.
5
A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
J Mol Diagn. 2017 Jan;19(1):99-106. doi: 10.1016/j.jmoldx.2016.08.004. Epub 2016 Nov 15.
6
High subclonal fraction of 17p deletion is associated with poor prognosis in multiple myeloma.
Blood. 2019 Mar 14;133(11):1217-1221. doi: 10.1182/blood-2018-10-880831. Epub 2019 Jan 28.
7
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
J Clin Pathol. 2018 Oct;71(10):895-899. doi: 10.1136/jclinpath-2018-205195. Epub 2018 May 14.
8
N-ras and p53 gene mutations are very rare events in multiple myeloma.
Int J Hematol. 1995 Aug;62(2):91-7. doi: 10.1016/0925-5710(95)00394-8.
9
Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma.
Haematologica. 2010 Nov;95(11):1973-6. doi: 10.3324/haematol.2010.023697. Epub 2010 Jul 15.
10
Copy number neutral loss of heterozygosity at 17p and homozygous mutations of TP53 are associated with complex chromosomal aberrations in patients newly diagnosed with myelodysplastic syndromes.
Leuk Res. 2016 Mar;42:7-12. doi: 10.1016/j.leukres.2016.01.009. Epub 2016 Jan 24.
引用本文的文献
1
Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.
Cancers (Basel). 2022 Oct 7;14(19):4901. doi: 10.3390/cancers14194901.
2
Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma.
Explor Target Antitumor Ther. 2021;2(1):65-106. doi: 10.37349/etat.2021.00034. Epub 2021 Feb 28.
3
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma.
Clin Cancer Res. 2022 Jul 1;28(13):2854-2864. doi: 10.1158/1078-0432.CCR-21-3695.
4
RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma.
J Pers Med. 2021 Sep 30;11(10):988. doi: 10.3390/jpm11100988.
5
Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing.
Front Genet. 2021 May 24;12:625019. doi: 10.3389/fgene.2021.625019. eCollection 2021.
6
Structural and functional characterization of multiple myeloma associated cytoplasmic poly(A) polymerase FAM46C.
Cancer Commun (Lond). 2021 Jul;41(7):615-630. doi: 10.1002/cac2.12163. Epub 2021 May 28.
7
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
Blood Cancer J. 2020 May 11;10(5):54. doi: 10.1038/s41408-020-0320-7.
8
Mutations In Thirty Hotspot Genes In Newly Diagnosed Chinese Multiple Myeloma Patients.
Onco Targets Ther. 2019 Nov 21;12:9999-10010. doi: 10.2147/OTT.S216289. eCollection 2019.
9
Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model.
Sci Rep. 2019 Dec 2;9(1):18062. doi: 10.1038/s41598-019-54407-4.
10
Applications and analysis of targeted genomic sequencing in cancer studies.
Comput Struct Biotechnol J. 2019 Nov 7;17:1348-1359. doi: 10.1016/j.csbj.2019.10.004. eCollection 2019.
本文引用的文献
1
Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness.
Blood. 2014 Apr 10;123(15):2378-88. doi: 10.1182/blood-2013-10-534271. Epub 2014 Feb 18.
2
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.
3
Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Nat Commun. 2014;5:2997. doi: 10.1038/ncomms3997.
4
Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Nature. 2013 Jul 11;499(7457):214-218. doi: 10.1038/nature12213. Epub 2013 Jun 16.
5
Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma.
Haematologica. 2013 Oct;98(10):1586-92. doi: 10.3324/haematol.2012.081083. Epub 2013 May 28.
6
Multiple myeloma is affected by multiple and heterogeneous somatic mutations in adhesion- and receptor tyrosine kinase signaling molecules.
Blood Cancer J. 2013 Feb 8;3(2):e102. doi: 10.1038/bcj.2012.47.
7
Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma.
Blood. 2012 Aug 2;120(5):1077-86. doi: 10.1182/blood-2012-03-412981. Epub 2012 May 9.
8
The genetic architecture of multiple myeloma.
Nat Rev Cancer. 2012 Apr 12;12(5):335-48. doi: 10.1038/nrc3257.
9
Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.
Clin Cancer Res. 2011 Dec 15;17(24):7776-84. doi: 10.1158/1078-0432.CCR-11-1791. Epub 2011 Oct 12.
10
Initial genome sequencing and analysis of multiple myeloma.
Nature. 2011 Mar 24;471(7339):467-72. doi: 10.1038/nature09837.
Zotero 插件